MA51287A - Analogues d'incrétine et leurs utilisations - Google Patents
Analogues d'incrétine et leurs utilisationsInfo
- Publication number
- MA51287A MA51287A MA051287A MA51287A MA51287A MA 51287 A MA51287 A MA 51287A MA 051287 A MA051287 A MA 051287A MA 51287 A MA51287 A MA 51287A MA 51287 A MA51287 A MA 51287A
- Authority
- MA
- Morocco
- Prior art keywords
- incretin
- analogues
- incretin analogues
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Details Of Garments (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762608644P | 2017-12-21 | 2017-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA51287A true MA51287A (fr) | 2021-03-31 |
Family
ID=65003515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA051287A MA51287A (fr) | 2017-12-21 | 2018-12-14 | Analogues d'incrétine et leurs utilisations |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US11834486B2 (fr) |
| EP (1) | EP3727425A1 (fr) |
| JP (2) | JP6987993B2 (fr) |
| KR (1) | KR102440323B1 (fr) |
| CN (1) | CN111511387A (fr) |
| AR (1) | AR113487A1 (fr) |
| AU (1) | AU2018388895B2 (fr) |
| BR (1) | BR112020010410A2 (fr) |
| CA (1) | CA3084004C (fr) |
| CL (1) | CL2020001636A1 (fr) |
| CO (1) | CO2020006253A2 (fr) |
| CR (1) | CR20200256A (fr) |
| DO (1) | DOP2020000124A (fr) |
| EA (1) | EA202091284A1 (fr) |
| EC (1) | ECSP20032306A (fr) |
| IL (2) | IL275469B2 (fr) |
| JO (1) | JOP20200136B1 (fr) |
| MA (1) | MA51287A (fr) |
| MX (2) | MX2020006547A (fr) |
| MY (1) | MY199545A (fr) |
| PE (1) | PE20200926A1 (fr) |
| PH (1) | PH12020551024A1 (fr) |
| SG (1) | SG11202004359YA (fr) |
| TW (2) | TWI810937B (fr) |
| UA (1) | UA127589C2 (fr) |
| WO (1) | WO2019125929A1 (fr) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI810937B (zh) * | 2017-12-21 | 2023-08-01 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| TWI744579B (zh) * | 2017-12-21 | 2021-11-01 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| TWI735917B (zh) | 2018-07-23 | 2021-08-11 | 美商美國禮來大藥廠 | Gip/glp1共促效劑化合物 |
| AR119471A1 (es) * | 2019-08-01 | 2021-12-22 | Lilly Co Eli | Compuestos agonistas de gipr |
| EP4017866A1 (fr) | 2019-08-19 | 2022-06-29 | Eli Lilly and Company | Procédés de fabrication d'analogues d'incrétine |
| AR120714A1 (es) * | 2019-12-18 | 2022-03-09 | Lilly Co Eli | Análogos de incretina y sus usos |
| IL294955A (en) * | 2020-01-23 | 2022-09-01 | Lilly Co Eli | Cobalt-agonist gip/glp1 compounds |
| EP4183419A4 (fr) * | 2020-07-17 | 2025-04-02 | Hanmi Pharm. Co., Ltd. | Utilisation thérapeutique d'une combinaison contenant un conjugué à action prolongée triplement agoniste ou un triple agoniste |
| IL299800A (en) * | 2020-08-14 | 2023-03-01 | Hanmi Pharm Ind Co Ltd | Pharmaceutical compositions containing long-acting conjugates of a triple agonist of the GLP-1/GIP glucagon receptor |
| WO2022090447A1 (fr) | 2020-10-30 | 2022-05-05 | Novo Nordisk A/S | Agonistes triples du récepteur de glp-1, gip et glucagon |
| TW202423476A (zh) | 2021-03-23 | 2024-06-16 | 美商美國禮來大藥廠 | 含腸促胰島素(incretin)類似物之組合物及其用途 |
| JP7803570B2 (ja) * | 2021-05-26 | 2026-01-21 | ザ ユナイテッド バイオテクノロジー（ヘンチン）シーオー．，エルティーディー． | マルチアゴニストおよびその使用 |
| CN115572326B (zh) * | 2021-06-21 | 2025-01-10 | 广东东阳光药业股份有限公司 | Glp-1、gcg和gip受体的三重激动剂 |
| BR112023027321A2 (pt) | 2021-06-23 | 2024-03-12 | Lilly Co Eli | Uso de um polipeptídeo, composição que compreende trirreceptor ggg, e dispositivo |
| EP4434536A4 (fr) * | 2021-11-19 | 2026-01-07 | Jiangsu Deyuan Pharmaceutical Co Ltd | Peptide agrafé et son utilisation |
| CN116162147B (zh) * | 2021-11-24 | 2023-10-03 | 成都奥达生物科技有限公司 | 一种长效胰岛素类似物 |
| AU2023348864A1 (en) * | 2022-09-28 | 2025-03-20 | Sunshine Lake Pharma Co., Ltd. | Glp-1/gcg/gip triple-receptor agonist and use thereof |
| JP2026502943A (ja) | 2022-12-30 | 2026-01-27 | アルギファルマ エーエス | 経口投与されるポリペプチド治療剤の全身バイオアベイラビリティを高める組成物および方法 |
| IL322205A (en) | 2023-01-31 | 2025-09-01 | Lilly Co Eli | GIP/GLP1/GCG trireceptor agonists and their uses |
| WO2024213022A1 (fr) * | 2023-04-11 | 2024-10-17 | 上海多米瑞生物技术有限公司 | Analogues d'incrétine et leur procédé de préparation, et utilisation |
| CN120349393A (zh) * | 2023-11-06 | 2025-07-22 | 成都奥达生物科技有限公司 | 一种三激动剂化合物 |
| CN120329412A (zh) * | 2023-11-06 | 2025-07-18 | 成都奥达生物科技有限公司 | 一种三激动剂化合物 |
| CN119241684B (zh) * | 2024-11-22 | 2025-02-25 | 徐州医科大学 | 一种肠促胰岛素类似物及其用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20120514A1 (es) | 2009-03-27 | 2012-05-14 | Glaxo Group Ltd | Fusiones y conjugados de agentes insulinotropicos o farmacos incretina con anticuerpos dab anti-albumina serica |
| AR092873A1 (es) | 2012-09-26 | 2015-05-06 | Cadila Healthcare Ltd | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon |
| AU2014345569B2 (en) | 2013-11-06 | 2020-08-13 | Zealand Pharma A/S | GIP-GLP-1 dual agonist compounds and methods |
| KR102310392B1 (ko) * | 2013-11-06 | 2021-10-13 | 질랜드 파마 에이/에스 | 글루카곤-ｇｌｐ-1-ｇｉｐ 삼원 효능제 화합물 |
| JO3575B1 (ar) * | 2015-01-09 | 2020-07-05 | Lilly Co Eli | مركبات مساعد مشترك من gip وglp-1 |
| WO2016198624A1 (fr) | 2015-06-12 | 2016-12-15 | Sanofi | Dérivés d'exendine 4 utilisés en tant qu'agonistes trigonaux des récepteurs du glp-1/glucagon/gip |
| AR104932A1 (es) * | 2015-06-22 | 2017-08-23 | Lilly Co Eli | Compuestos co-agonistas del glucagón y péptido-1 similar al glugacón (glp-1) |
| JP6712323B2 (ja) | 2015-12-31 | 2020-06-17 | ハンミ ファーマシューティカル カンパニー リミテッド | グルカゴン、ｇｌｐ−１及びｇｉｐ受容体のすべてに活性を有する三重活性体 |
| EP3217027A1 (fr) | 2016-03-08 | 2017-09-13 | HILTI Aktiengesellschaft | Élement de revetement large destine a entourer une tige d'ancrage |
| TWI810937B (zh) * | 2017-12-21 | 2023-08-01 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
-
2018
- 2018-12-05 TW TW111118551A patent/TWI810937B/zh active
- 2018-12-05 TW TW107143623A patent/TWI767095B/zh active
- 2018-12-06 AR ARP180103573A patent/AR113487A1/es unknown
- 2018-12-14 MY MYPI2020003206A patent/MY199545A/en unknown
- 2018-12-14 MA MA051287A patent/MA51287A/fr unknown
- 2018-12-14 UA UAA202002893A patent/UA127589C2/uk unknown
- 2018-12-14 CN CN201880082714.8A patent/CN111511387A/zh active Pending
- 2018-12-14 KR KR1020207017385A patent/KR102440323B1/ko active Active
- 2018-12-14 MX MX2020006547A patent/MX2020006547A/es unknown
- 2018-12-14 PE PE2020000800A patent/PE20200926A1/es unknown
- 2018-12-14 BR BR112020010410-8A patent/BR112020010410A2/pt unknown
- 2018-12-14 JP JP2020532952A patent/JP6987993B2/ja active Active
- 2018-12-14 IL IL275469A patent/IL275469B2/en unknown
- 2018-12-14 WO PCT/US2018/065605 patent/WO2019125929A1/fr not_active Ceased
- 2018-12-14 CA CA3084004A patent/CA3084004C/fr active Active
- 2018-12-14 US US16/769,015 patent/US11834486B2/en active Active
- 2018-12-14 CR CR20200256A patent/CR20200256A/es unknown
- 2018-12-14 SG SG11202004359YA patent/SG11202004359YA/en unknown
- 2018-12-14 EP EP18830614.6A patent/EP3727425A1/fr active Pending
- 2018-12-14 IL IL325352A patent/IL325352A/en unknown
- 2018-12-14 EA EA202091284A patent/EA202091284A1/ru unknown
- 2018-12-14 AU AU2018388895A patent/AU2018388895B2/en active Active
-
2020
- 2020-05-22 CO CONC2020/0006253A patent/CO2020006253A2/es unknown
- 2020-06-02 JO JOJO/P/2020/0136A patent/JOP20200136B1/ar active
- 2020-06-17 PH PH12020551024A patent/PH12020551024A1/en unknown
- 2020-06-17 CL CL2020001636A patent/CL2020001636A1/es unknown
- 2020-06-17 DO DO2020000124A patent/DOP2020000124A/es unknown
- 2020-06-19 EC ECSENADI202032306A patent/ECSP20032306A/es unknown
- 2020-07-13 MX MX2025003745A patent/MX2025003745A/es unknown
-
2021
- 2021-12-01 JP JP2021195036A patent/JP2022043082A/ja not_active Withdrawn
-
2023
- 2023-10-30 US US18/497,390 patent/US20240190936A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51288A (fr) | Analogues d'incrétine et leurs utilisations | |
| EP3817822A4 (fr) | Agents de dégradation de protéines et leurs utilisations | |
| MA50618A (fr) | Polyrhérapies et leurs utilisations | |
| EP3749318A4 (fr) | Raltitrexed gamma-polyglutamaté et utilisations associées | |
| EP3749315A4 (fr) | Raltitrexed alpha-polyglutamaté et utilisations associées | |
| EP3471727A4 (fr) | Inhibiteurs de cxcr4 et leurs utilisations | |
| EP3472129A4 (fr) | Inhibiteurs de cxcr4 et leurs utilisations | |
| EP3600273A4 (fr) | Inhibiteurs de cd73 et leurs utilisations | |
| EP3445365A4 (fr) | Inhibiteurs d'ezh2 et leurs utilisations | |
| EP3749314A4 (fr) | Méthotrexate alpha-polyglutamaté et utilisations associées | |
| EP3383916A4 (fr) | Anticorps anti-cd73 et leurs utilisations | |
| EP3504243A4 (fr) | Anticorps anti-tim-3 et leurs utilisations | |
| EP3413816A4 (fr) | Compositions hydratantes et utilisations associées | |
| EP3389702A4 (fr) | Anticorps anti-lag-3 et leurs utilisations | |
| EP3426288A4 (fr) | Anticorps anti-pacap et leurs utilisations | |
| EP3344275A4 (fr) | Macrocycles peptidomimétiques et leurs utilisations | |
| EP3790861A4 (fr) | Compositions sénolytiques et utilisations associées | |
| MA42622A (fr) | Agents de liaison à tigit et leurs utilisations | |
| EP2968443A4 (fr) | Analogues d'hepcidine et leurs utilisations | |
| EP3439741A4 (fr) | Antagonistes d'alk7 et leurs utilisations | |
| EP3294318A4 (fr) | Macrocycles peptidomimétiques et leurs utilisations | |
| EP3283516A4 (fr) | Anticorps anti-pacap et leurs utilisations | |
| EP3471726A4 (fr) | Inhibiteurs de cxcr4 et leurs utilisations | |
| MA45125A (fr) | Anticorps anti-alpha-synucléine et leurs utilisations | |
| EP3364958A4 (fr) | Modulateurs d'interaction sestrine-gator2 et leurs utilisations |